^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | Leiomyosarcoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Imlygic (talimogene laherparepvec) (GM-CSF agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
54: TNT: Talimogene Laherparepvec (An Oncolytic Virus Expressing GM-CSF), Nivolumab and Trabectedin for Advanced Leiomyosarcoma: A Phase 2 Study [NCT# 03886311]
Published date:
05/02/2023
Excerpt:
The median PFS was 7 months (range: 3- 18; Trabectedin alone for LMS= 4.3 mos; Dacarbazine alone = 1.6 mos); 6-month PFS rate, 55%; median OS 18.2 months (range: 4- 32); 6-month OS rate, 91%....patients with PR were ER+/PR+ and had uterine LMS….These results suggest that (1) By indirect comparison, the combination regimen using Talimogene laherparepvec, Nivolumab & Trabectedin may be more effective as second/third-line/fourth therapy for advanced leiomyosarcoma with manageable toxicity...The best responders are patients with HR+ uterine LMS.
Secondary therapy:
trabectedin
Trial ID:
